Racial and Ethnic Minority Acceleration for Health Equity Consortium U01

种族和族裔少数族裔加速健康公平联盟 U01

• 批准号: 10823572
• 负责人: CLAUDIA R0SE BAQUET
• 金额: $ 50万
• 依托单位: UNIVERSITY OF MARYLAND BALTIMORE
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-06-01 至 2025-05-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10823572
• 关键词: Racial; Ethnic; Minority; Acceleration; Health

PROJECT SUMMARY/ABSTRACT This proposal responds to FDA's OMHHE desire to accelerate efforts to address racial and ethnic minority and health equity through its REACH Consortium. This two-phase “health equity acceleration” U01 application is submitted to participate in the FDA OMHHE Health Equity Innovation Award for “Racial & Ethnic Minority Acceleration Consortium for Health Equity (REACH) (U01)” focused on advancing “minority health and health equity focused research, outreach, and communications as well as support training and mentoring of diverse HBCU advanced students, fellows, and researchers.” The proposed program and projects benefit from established partnerships and recognized leadership between the PATIENTS Program at the University of Maryland Baltimore, the Pastor of Mt. Lebanon Baptist Church (Pastor Lance MLBC), a rural Health Equity expert (Dr. Datcher), and two Historically Black Colleges/Universities (HBCUs): Coppin State University (CSU) Helene Fuld School of Nursing (Dean Tilghman), and Xavier University of Louisiana (XULA) College of Pharmacy (Dean Kennedy). Two pilot projects/programs submitted in this application encompass two RFA “pillars' of “equity of voices” and equity in clinical trials” which will be developed under Phase 1: a) A Pilot curriculum and potential FDA OMHHE rotations on “Regulatory Issues and Health Equity” for advanced students and faculty in HBCUs in Pharmacy and Nursing; and b) A Pilot research project which more beyond clinical trial barrier identification to development of strategies to address barriers to clinical trial diversity, in order to increase trustworthiness, transparency in sponsors and researchers, and increase willingness to participate in trials. In Phase 1, planning, administrative procedures and logistics will be developed and in Phase 2, the pilot project and program will be implemented. SPECIFIC AIMS for the two-phase proposal: AIM 1 ADMINISTRATIVE CORE: Establish the Administrative Core (AC) to co-institute policies and procedures with the Community and Health Professional Advisory Board (CHPAB) in order to cultivate effective interactions with the FDA OMHHE and its REACH Consortium. AIM 2 (EQUITY OF VOICES): Co-develop, with guidance of the CHPAB and input from the FDA OMHHE, a curriculum on “Regulatory Science and Health Equity,” and potential rotations at FDA OMHHE for HBCU fellows, postdoctoral researchers, and graduate students. AIM 3 (EQUITY IN CLINICAL TRIALS): Conduct pilot research designed to delineate strategies for overcoming identified barriers to clinical trials participation for African Americans, in order to increase equity in participation of underrepresented minority racial and ethnic groups in clinical trials.

项目摘要/摘要 该提案响应了 FDA 的 OMHHE 愿望 通过 REACH 加速解决种族和族裔少数群体以及健康公平问题 此两阶段“健康公平加速”U01 申请已提交给 参加 FDA OMHHE 健康公平创新奖“种族和少数族裔 健康公平加速联盟 (REACH) (U01)”专注于推进“少数族裔 以健康和健康公平为重点的研究、外展、沟通以及支持 培训和指导不同的 HBCU 高级学生、研究员和研究人员。” 拟议的方案和项目受益于已建立的伙伴关系和公认的 马里兰大学巴尔的摩分校牧师牧师之间的患者计划之间的领导 黎巴嫩山浸信会教堂（Lance MLBC 牧师）、农村健康公平专家（Datcher 博士）、 和两所历史悠久的黑人学院/大学 (HBCU)：科平州立大学 (CSU) 海伦·富尔德护理学院 (Dean Tilghman) 和路易斯安那州泽维尔大学 (XULA) 药学院（迪恩·肯尼迪）在此申请中提交了两个试点项目/计划。 包括“声音公平”和“临床试验公平”这两个 RFA“支柱”，这将是 在第一阶段开发：a) 试点课程和潜在的 FDA OMHHE 轮换 面向 HBCU 高级学生和教师的“监管问题和健康公平” 药学和护理；b) 超越临床试验障碍的试点研究项目 确定制定战略以解决临床试验多样性的障碍，以便 提高申办者和研究人员的可信度和透明度，并提高参与的意愿 在第一阶段，规划、行政程序和后勤工作将得到解决。 制定了具体目标，并在第二阶段实施试点项目和计划。 对于两阶段提案： 目标 1 行政核心：建立行政核心 (AC) 共同制定 社区和健康专业咨询委员会 (CHPAB) 的政策和程序 以培养与 FDA OMHHE 及其 REACH 联盟的有效互动。 目标 2（平等的声音）：在 CHPAB 的指导和来自 FDA OMHHE，“监管科学和健康公平”课程以及潜在轮换 FDA OMHHE 面向 HBCU 研究员、博士后研究人员和研究生 AIM 3。 （临床试验的公平性）：进行旨在描绘策略的试点研究 克服非裔美国人参与临床试验的已知障碍，以便 增加临床中代表性不足的少数种族和族裔群体的公平参与 试验。